Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis

Veterinary Anaesthesia and Analgesia

Volumn 40, Issue 4, 2013, Pages 440-448

  Guedes, Alonso G P ^a   Morisseau, Christophe ^b   Sole, Albert ^a   Soares, Joao H N ^a   Ulu, Arzu ^b   Dong, Hua ^b   Hammock, Bruce D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Analgesia; Antinociception; Arterial blood pressure; Equine; Nociception; Pain management

Indexed keywords

ANIMALIA; EQUIDAE;

EID: 84879159163     PISSN: 14672987     EISSN: 14672995     Source Type: Journal    
DOI: 10.1111/vaa.12030     Document Type: Article

References (46)

1. Belknap JK, Giguere S, Pettigrew A et al. (2007) Lamellar pro-inflammatory cytokine expression patterns in laminitis at the developmental stage and at the onset of lameness: innate vs. adaptive immune response. Equine Vet J 39, 42-47.
2. Beretta C, Garavaglia G, Cavalli M (2005) COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res 52, 302-306.
3. Bussieres G, Jacques C, Lainay O et al. (2008) Development of a composite orthopaedic pain scale in horses. Res Vet Sci 85, 294-306.
4. Chiamvimonvat N, Ho CM, Tsai HJ et al. (2007) The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 50, 225-237.
5. Davis JL, Posner LP, Elce Y (2007) Gabapentin for the treatment of neuropathic pain in a pregnant horse. J Am Vet Med Assoc 231, 755-758.
6. Decker M, Arand M, Cronin A (2009) Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch Toxicol 83, 297-318.
7. Driessen B, Bauquier SH, Zarucco L (2010) Neuropathic pain management in chronic laminitis. Vet Clin North Am Equine Pract 26, 315-337.
8. Eckhardt K, Ammon S, Hofmann U et al. (2000) Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg 91, 185-191.
9. Hood DM (1999) The pathophysiology of developmental and acute laminitis. Vet Clin North Am Equine Pract 15, 321-343.
10. Hood DM, Grosenbaugh DA, Mostafa MB et al. (1993) The role of vascular mechanisms in the development of acute equine laminitis. J Vet Intern Med 7, 228-234.
11. Hwang SH, Tsai HJ, Liu JY et al. (2007) Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 50, 3825-3840.
12. Imig JD, Hammock BD (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8, 794-805.
13. Inceoglu B, Jinks SL, Schmelzer KR et al. (2006) Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci 79, 2311-2319.
14. Inceoglu B, Schmelzer KR, Morisseau C et al. (2007) Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 82, 42-49.
15. Inceoglu B, Jinks SL, Ulu A et al. (2008) Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci U S A 105, 18901-18906.
16. Inceoglu B, Wagner K, Schebb NH et al. (2011) Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP. Proc Natl Acad Sci U S A 108, 5093-5097.
17. Inceoglu B, Wagner KM, Yang J et al. (2012) Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes. Proc Natl Acad Sci U S A 109, 11390-11395.
18. Jones E, Vinuela-Fernandez I, Eager RA et al. (2007) Neuropathic changes in equine laminitis pain. Pain 132, 321-331.
19. Lakritz J, Winder BS, Noorouz-Zadeh J et al. (2000) Hepatic and pulmonary enzyme activities in horses. Am J Vet Res 61, 152-157.
20. Liu J, Feng X, Yu M et al. (2007) Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain. Neurosci Lett 412, 268-272.
21. Liu Y, Uboh CE, Soma LR et al. (2011) Analysis of gabapentin in equine plasma with measurement uncertainty estimation by liquid chromatography-tandem mass spectrometry. J Anal Toxicol 35, 75-84.
22. Moalem G, Tracey DJ (2006) Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev 51, 240-264.
23. Morisseau C, Hammock BD (2005) Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 45, 311-333.
24. Morisseau C, Hammock BD (2008) Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical. Pest Manag Sci 64, 594-609.
25. Morisseau C, Newman JW, Tsai HJ et al. (2006) Peptidyl-urea based inhibitors of soluble epoxide hydrolases. Bioorg Med Chem Lett 16, 5439-5444.
26. Morisseau C, Inceoglu B, Schmelzer K et al. (2010) Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J Lipid Res 51, 3481-3490.
27. Murakami M (2011) Lipid mediators in life science. Exp Anim 60, 7-20.
28. Node K, Huo Y, Ruan X et al. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276-1279.
29. Parks A, O'Grady SE (2003) Chronic laminitis: current treatment strategies. Vet Clin North Am Equine Pract 19, 393-416.
30. Peroni JF, Moore JN, Noschka E et al. (2006) Predisposition for venoconstriction in the equine laminar dermis: implications in equine laminitis. J Appl Physiol 100, 759-763.
31. Revermann M (2010) Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man. Curr Opin Pharmacol 10, 173-178.
32. Schmelzer KR, Kubala L, Newman JW et al. (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A 102, 9772-9777.
33. Schmelzer KR, Inceoglu B, Kubala L et al. (2006) Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 103, 13646-13651.
34. Sumano Lopez H, Hoyas Sepulveda ML, Brumbaugh GW (1999) Pharmacologic and alternative therapies for the horse with chronic laminitis. Vet Clin North Am Equine Pract 15, 495-516.
35. Taylor PM, Pascoe PJ, Mama KR (2002) Diagnosing and treating pain in the horse. Where are we today? Vet Clin North Am Equine Pract 18, 1-19.
36. Teixeira Neto FJ, McDonell WN, Black WD et al. (2004) Effects of glycopyrrolate on cardiorespiratory function in horses anesthetized with halothane and xylazine. Am J Vet Res 65, 456-463.
37. Terry RL, McDonnell SM, Van Eps AW et al. (2010) Pharmacokinetic profile and behavioral effects of gabapentin in the horse. J Vet Pharmacol Ther 33, 485-494.
38. Tokuyama S, Nakamoto K (2011) Unsaturated Fatty acids and pain. Biol Pharm Bull 34, 1174-1178.
39. Tsai HJ, Hwang SH, Morisseau C et al. (2010) Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. Eur J Pharm Sci 40, 222-238.
40. Ulu A, Appt S, Morisseau C et al. (2011) Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. Br J Pharmacol 165, 1401-1412
41. Vale ML, Benevides VM, Sachs D et al. (2004) Antihyperalgesic effect of pentoxifylline on experimental inflammatory pain. Br J Pharmacol 143, 833-844.
42. Vinuela-Fernandez I, Jones E, Chase-Topping ME et al. (2011) Comparison of subjective scoring systems used to evaluate equine laminitis. Vet J 188, 171-177.
43. Wagner K, Inceoglu B, Gill SS et al. (2011a) Epoxygenated fatty acids and soluble epoxide hydrolase inhibition: novel mediators of pain reduction. J Agric Food Chem 59, 2816-2824.
44. Wagner K, Inceoglu B, Hammock BD (2011b) Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception. Prostaglandins Other Lipid Mediat 96, 76-83.
45. You Y, Uboh CE, Soma LR et al. (2009) Screening, quantification, and confirmation of phenylbutazone and oxyphenbutazone in equine plasma by liquid chromatography-tandem mass spectrometry. J Anal Toxicol 33, 41-50.
46. Yu Z, Xu F, Huse LM et al. (2000) Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87, 992-998.